

# FALLOPIAN TUBE STAGING FORM

CLINICAL <i>Extent of disease before any treatment</i>	STAGE CATEGORY DEFINITIONS		PATHOLOGIC <i>Extent of disease through completion of definitive surgery</i>	
<input type="checkbox"/> y clinical – staging completed after neoadjuvant therapy but before subsequent surgery	<b>TUMOR SIZE:</b> _____	<b>LATERALITY:</b> <input type="checkbox"/> left <input type="checkbox"/> right <input type="checkbox"/> bilateral	<input type="checkbox"/> y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery	
<b>TNM CATEGORY</b> <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T1a <input type="checkbox"/> T1b <input type="checkbox"/> T1c  <input type="checkbox"/> T2 <input type="checkbox"/> T2a <input type="checkbox"/> T2b <input type="checkbox"/> T2c <input type="checkbox"/> T3  <input type="checkbox"/> T3a <input type="checkbox"/> T3b  <input type="checkbox"/> T3c	<b>FIGO STAGE</b>  * I IA IB IC  II IIA IIB IIC III  IIIA IIIB  IIIC	<b>PRIMARY TUMOR (T)</b> Primary tumor cannot be assessed No evidence of primary tumor Carcinoma <i>in situ</i> (limited to tubal mucosa) Tumor limited to the fallopian tube(s) Tumor limited to one tube, without penetrating the serosal surface; no ascites Tumor limited to both tubes, without penetrating the serosal surface; no ascites Tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings Tumor involves one or both fallopian tubes with pelvic extension Extension and/or metastasis to the uterus and/or ovaries Extension to other pelvic structures Pelvic extension with malignant cells in ascites or peritoneal washings Tumor involves one or both fallopian tubes, with peritoneal implants outside the pelvis Microscopic peritoneal metastasis outside the pelvis Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension Peritoneal metastasis outside the pelvis and more than 2 cm in diameter  * FIGO no longer includes Stage 0 (Tis) Note: Liver capsule metastasis is T3/Stage III; liver parenchymal metastasis M1/Stage IV. Pleural effusion must have positive cytology for M1/Stage IV.	<b>TNM CATEGORY</b> <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Tis <input type="checkbox"/> T1  <input type="checkbox"/> T2  <input type="checkbox"/> T3  <input type="checkbox"/> T4	<b>FIGO STAGE</b>  * IA IB II IVA
<b>TNM CATEGORY</b> <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1	<b>FIGO STAGE</b>   IIIC	<b>REGIONAL LYMPH NODES (N)</b> Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis	<b>TNM CATEGORY</b> <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1	<b>FIGO STAGE</b>   IIIC
<b>TNM CATEGORY</b> <input type="checkbox"/> M0 <input type="checkbox"/> M1	<b>FIGO STAGE</b>  IV	<b>DISTANT METASTASIS (M)</b> No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis (excludes metastasis within the peritoneal cavity)	<b>TNM CATEGORY</b> <input type="checkbox"/> M1	<b>FIGO STAGE</b> IV

<b>HOSPITAL NAME/ADDRESS</b>	<b>PATIENT NAME/INFORMATION</b>
------------------------------	---------------------------------

(continued on next page)

# FALLOPIAN TUBE STAGING FORM

## ANATOMIC STAGE • PROGNOSTIC GROUPS

CLINICAL				PATHOLOGIC			
GROUP	T	N	M	GROUP	T	N	M
<input type="checkbox"/> 0*	Tis	N0	M0	<input type="checkbox"/> 0*	Tis	N0	M0
<input type="checkbox"/> I	T1	N0	M0	<input type="checkbox"/> I	T1	N0	M0
<input type="checkbox"/> IA	T1a	N0	M0	<input type="checkbox"/> IA	T1a	N0	M0
<input type="checkbox"/> IB	T1b	N0	M0	<input type="checkbox"/> IB	T1b	N0	M0
<input type="checkbox"/> IC	T1c	N0	M0	<input type="checkbox"/> IC	T1c	N0	M0
<input type="checkbox"/> II	T2	N0	M0	<input type="checkbox"/> II	T2	N0	M0
<input type="checkbox"/> IIA	T2a	N0	M0	<input type="checkbox"/> IIA	T2a	N0	M0
<input type="checkbox"/> IIB	T2b	N0	M0	<input type="checkbox"/> IIB	T2b	N0	M0
<input type="checkbox"/> IIC	T2c	N0	M0	<input type="checkbox"/> IIC	T2c	N0	M0
<input type="checkbox"/> III	T3	N0	M0	<input type="checkbox"/> III	T3	N0	M0
<input type="checkbox"/> IIIA	T3a	N0	M0	<input type="checkbox"/> IIIA	T3a	N0	M0
<input type="checkbox"/> IIIB	T3b	N0	M0	<input type="checkbox"/> IIIB	T3b	N0	M0
<input type="checkbox"/> IIIC	T3c	N0	M0	<input type="checkbox"/> IIIC	T3c	N0	M0
	Any T	N1	M0		Any T	N1	M0
<input type="checkbox"/> IV	Any T	Any N	M1	<input type="checkbox"/> IV	Any T	Any N	M1

\*FIGO no longer includes Stage 0 (Tis)

☐ Stage unknown

PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)		<b>General Notes:</b> For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.  <b>m suffix</b> indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.  <b>y prefix</b> indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.  <b>r prefix</b> indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.  <b>a prefix</b> designates the stage determined at autopsy: aTNM.									
<b>REQUIRED FOR STAGING:</b> None  <b>CLINICALLY SIGNIFICANT:</b> FIGO Stage: _____ Tumor location : _____ (fimbria, isthmus, unknown) Pelvic and paraaortic nodal status: Pelvic _____ Paraaortic _____ (report as number of nodes removed/number of nodes involved with tumor)	<b>Histologic Grade (G) (also known as overall grade)</b> <table style="width: 100%;"> <tr> <th style="text-align: left;">Grading system</th> <th style="text-align: left;">Grade</th> </tr> <tr> <td><input type="checkbox"/> 2 grade system</td> <td><input type="checkbox"/> Grade I or 1</td> </tr> <tr> <td><input type="checkbox"/> 3 grade system</td> <td><input type="checkbox"/> Grade II or 2</td> </tr> <tr> <td><input type="checkbox"/> 4 grade system</td> <td><input type="checkbox"/> Grade III or 3</td> </tr> <tr> <td><input type="checkbox"/> No 2, 3, or 4 grade system is available</td> <td><input type="checkbox"/> Grade IV or 4</td> </tr> </table> <b>ADDITIONAL DESCRIPTORS</b> <b>Lymphatic Vessel Invasion (L) and Venous Invasion (V)</b> have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.		Grading system	Grade	<input type="checkbox"/> 2 grade system	<input type="checkbox"/> Grade I or 1	<input type="checkbox"/> 3 grade system	<input type="checkbox"/> Grade II or 2	<input type="checkbox"/> 4 grade system	<input type="checkbox"/> Grade III or 3	<input type="checkbox"/> No 2, 3, or 4 grade system is available
Grading system	Grade										
<input type="checkbox"/> 2 grade system	<input type="checkbox"/> Grade I or 1										
<input type="checkbox"/> 3 grade system	<input type="checkbox"/> Grade II or 2										
<input type="checkbox"/> 4 grade system	<input type="checkbox"/> Grade III or 3										
<input type="checkbox"/> No 2, 3, or 4 grade system is available	<input type="checkbox"/> Grade IV or 4										

☐ Lymph-Vascular Invasion Not Present (absent)/Not Identified  
☐ Lymph-Vascular Invasion Present/Identified  
☐ Not Applicable  
☐ Unknown/Indeterminate

HOSPITAL NAME/ADDRESS	PATIENT NAME/INFORMATION
-----------------------	--------------------------

(continued from previous page)

## FALLOPIAN TUBE STAGING FORM

### **Residual Tumor (R)**

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

### **General Notes (continued):**

**surgical margins** is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

**neoadjuvant treatment** is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

☐ Clinical stage was used in treatment planning (describe): \_\_\_\_\_

☐ National guidelines were used in treatment planning    ☐ NCCN    ☐ Other (describe): \_\_\_\_\_

\_\_\_\_\_  
Physician signature

\_\_\_\_\_  
Date/Time



**HOSPITAL NAME/ADDRESS**

**PATIENT NAME/INFORMATION**

(continued on next page)

FALLOPIAN TUBE STAGING FORM

**Illustration**  
Indicate on diagram primary tumor and regional nodes involved.



HOSPITAL NAME/ADDRESS	PATIENT NAME/INFORMATION

(continued from previous page)